Company ProfilePremium

Teoxane Laboratories

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Teoxane Laboratories - Healthcare showcase

Year Founded & Workforce

2003

500 Employees

Industry

Healthcare

Services

Dermal Fillers
T

Teoxane Laboratories Employee Contacts

15 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Teoxane Laboratories Overview

Company Headquarters: Geneva, Switzerland

Founded: 2003

Workforce: ~500

Company Working: Teoxane Laboratories (Teoxane) is specialized in the designing and manufacturing of hyaluronic acid (HA)-based dermal fillers and cosmeceuticals. The company offers skin treatment products that are used for reducing wrinkles, restoring youthful volume to the face, and treating the neck and décolleté with-looking natural results. It focuses on medical devices, aesthetic products, skin care, beauty, anti-aging solutions, dermal fillers, and dermis redensification. The company has a strong distribution network in more than 95 countries as well as more than 10 subsidiaries in France, UK, Italy, Spain, Germany, Switzerland, Poland, Australia, Russia, Dubai, and Singapore.

Strategy

Teoxane focuses on developing innovative technologies to deliver best-in-class solutions. It also aims at providing quality products and services to maintain a diversified business with a strong pipeline of new products. The company has been taking steps to expand its sales in emerging markets such as India and China. Teoxane also focuses on maintaining and enhancing customer satisfaction by providing quality products and improving customer support and services.

Company Snapshot

500

Employees

2003

Founded

Geneva, Switzerland

Headquarters

SWOT Analysis

Strengths

  • Recognized brand
  • Strong global presence
  • Provides high-quality and cost-effective products
  • Strong pipeline of dermal filler products

Weaknesses

  • Limited workforce

Opportunities

  • Investing in R&D
  • Customer engagement through online channels
  • Product innovation and rising research and development activity

Threats

  • Increasing rivalry in the market
  • Rapid technological developments
  • Increasing raw material costs

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
January 2020AgreementTeoxane announced an exclusive distribution agreement with Revance Therapeutics (US). This agreement provides Revance Therapeutics the right to commercialize Teoxane’s RHA line of fillers in the US, starting with its FDA-approved RHA 2, RHA 3, and RHA 4 products, as well as Teoxane’s RHA 1 dermal filler, which is currently undergoing clinical trials. This agreement provides support for the expansion of the company’s dermal fillers business in the US.

Product Offering

  • Teoxane Laboratories
    • Dermal Fillers

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.